5472-38-8

Basic information

• Product Name: DIETHYL FORMYLSUCCINATE
• Synonyms: DIETHYL FORMYLSUCCINATE;diethyl 2-forMylsuccinate;Butanedioic acid,2-forMyl-, 1,4-diethyl ester;Diethyl 2-formylbutanedioate;Diethyl 2-formylbutanedioat
• CAS NO: 5472-38-8
• Molecular Formula: C₉H₁₄O₅
• Molecular Weight: 202.20446
• Mol File: 5472-38-8.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 260.32°C (rough estimate)
• Flash Point: 119.9°C
• Appearance: /
• Density: 1.1840 (rough estimate)
• Vapor Pressure: 0.00363mmHg at 25°C
• Refractive Index: 1.4486 (estimate)
• Storage Temp.: 2-8°C
• PKA: 6.85±0.59(Predicted)
• CAS DataBase Reference: DIETHYL FORMYLSUCCINATE(CAS DataBase Reference)
• NIST Chemistry Reference: DIETHYL FORMYLSUCCINATE(5472-38-8)
• EPA Substance Registry System: DIETHYL FORMYLSUCCINATE(5472-38-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• Hazardous Substances Data: 5472-38-8(Hazardous Substances Data)

Usage

General Description

DIETHYL FORMYLSUCCINATE is a chemical compound with the molecular formula C9H16O4. It is a clear, colorless liquid that is commonly used in organic synthesis as a reagent for the preparation of various organic compounds. DIETHYL FORMYLSUCCINATE is a formylating agent, meaning it is capable of introducing the formyl group (-CHO) into organic molecules. It is also used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other fine chemicals. Additionally, DIETHYL FORMYLSUCCINATE is utilized in the production of fragrances and flavoring agents, as well as in the manufacturing of polymers and plastics. It is important to handle this chemical with care and follow proper safety protocols, as it can be hazardous if not used properly.

InChI:InChI=1/C9H14O5/c1-3-13-8(11)5-7(6-10)9(12)14-4-2/h6-7H,3-5H2,1-2H3

Upstream product

• 623-91-6 diethyl Fumarate 
• 71-43-2 benzene 
• 60-29-7 diethyl ether 
• 141-05-9 Diethyl maleate 
• 109-94-4 formic acid ethyl ester 
• 123-25-1 succinic acid diethyl ester 
• 585-68-2 aconic acid 
• 64-17-5 ethanol 

Downstream Products

• 124391-75-9 3-tetrahydrofuranmethanol 
• 6482-32-2 2-(hydroxymethyl)butane-1,4-diol 
• 29571-44-6 ethyl 2-[4-hydroxy-2-(methylthio)pyrimidin-5-yl]acetate 
• 5810-64-0 ethyl 2-(4-hydroxy-2-phenylpyrimidin-5-yl)acetate 
• 14273-42-8 ethyl 2-(4-hydroxy-2-methylpyrimidin-5-yl)acetate 
• 6214-46-6 ethyl (4-hydroxypyrimidin-5-yl)acetate 
• 61727-34-2 ethyl [4-chloro-2-(methylsulfanyl)pyrimidin-5-yl]acetate 
• 5810-63-9 ethyl 2-(4-chloro-2-phenylpyrimidin-5-yl)acetate 
• 118801-71-1 5,7-dihydro-2-methyl-6H-pyrrolo[2,3-d]pyrimidin-6-one 
• 5817-96-9 5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one 
• 91560-17-7 2-(4-amino-2-phenylpyrimidin-5-yl)acetamide 

Relevant articles and documents

1 Methyl 3 piperidone and 1 methyl 3 pyrrolidone derivatives from a Dieckmann reaction

-

CYCLIN-DEPENDENT KINASE INHIBITORS

Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are useful in the treatment or alleviation of protein kinase associated disorders, including cancer, infectious diseases, autoimmune diseases, or cardiovascular diseases.

Synthesis and in?vitro evaluation of new fluorinated quinoline derivatives with high affinity for PDE5: Towards the development of new PET neuroimaging probes

The increasing incidence of Alzheimer's disease (AD) worldwide is a major public health problem. Current treatments provide only palliative solutions with significant side effects. Therefore, new efficient treatment options and novel early diagnosis tools are urgently needed. Recently, strong pre-clinical evidences suggested that phosphodiesterase 5 (PDE5) may be clinically relevant both as biomarker and drug-target in AD. In this study, we intended to develop a new radiofluorinated tracer for the visualisation of PDE5 in brain using PET imaging. Based on currently known PDE5 inhibitors, a series of novel fluorinated compounds bearing a quinoline core have been synthesised via multi-steps reaction pathways. Their affinity for PDE5 and selectivity over other PDE families have been investigated. According to the data collected from this in vitro screening, fluorinated derivatives 24a, b bearing a fluoroethoxy group at the C-3 position of the quinoline core appeared to be the most promising structures and will be further radiolabelled with fluorine-18 for in vitro and in vivo evaluations as PET radiotracer for neuroimaging of PDE5.